Multinational drug firm Pfizer said it has entered into multiple agreements with the Hyderabad-based Aurobindo pharma to sell generic medicines in US and Europe, as part of expanding its Established Products Business Units.
Established Products Business Unit (EPBU) is an arm of the US-based pharma major which focusing on commercialization of those drugs, whose market exclusivity and patents have expired.
Under the agreement, Pfizer has acquired the right to sell 39 generic solid oral dose products in US and 20 in Europe coupled with additional 11 products in France, Pfizer said in a statement.
"Going forward, Pfizer plans to expand the Established Product Business Unit's product portfolio through additional activities with Aurobindo and other companies to provide our customers with a wider product offering," Pfizer EPBU President and General Manager David Simmons said.
These medicines cover a broad range of therapeutic areas including cardiovascular disease and central nervous system disorders, and these drugs would be sold in US through its subsidiary, the company said.